Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center

Keros Therapeutics (KROS) announced that it has entered into an agreement with the Massachusetts General Hospital, MGH, for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis, ALS, within the Healey ALS MyMatch program, led by the Sean M. Healey & AMG Center for ALS at Mass General Brigham. “We are proud to be selected to the ALS MyMatch program to collaborate with the Healey & AMG Center at Mass General,” said Jasbir Seehra, Ph.D., President and Chief Executive Officer of Keros. “Rinvatercept represents a potentially novel approach to treat patients with ALS. Based on the data we have generated to date, we believe there is a strong scientific rationale for the potential of rinvatercept to preserve muscle strength and function and improve quality of life in patients with ALS.”